Form 8-K - Current report:
SEC Accession No. 0001641172-25-008417
Filing Date
2025-05-02
Accepted
2025-05-02 17:15:07
Documents
16
Period of Report
2025-04-30
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT form8-k.htm   iXBRL 8-K 34420
2 EX-3.1 ex3-1.htm EX-3.1 3248
3 EX-10.1 ex10-1.htm EX-10.1 12440
4 EX-10.2 ex10-2.htm EX-10.2 12280
  Complete submission text file 0001641172-25-008417.txt   246666

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE mtnb-20250430.xsd EX-101.SCH 3038
6 XBRL LABEL FILE mtnb-20250430_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE mtnb-20250430_pre.xml EX-101.PRE 22374
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3672
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 25909934
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)